From: Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study
No PPI users
(n = 1,000)
PPI users
Difference
No. of complications (95% CI)
13.8 (13.7 to 13.9)
3.60 (3.56 to 3.64)
10.2
Costsa (95% CI)
€ 115,676 (114,874 to 116,493)
€ 165,770 (160,789 to 173,444)
€ 50,094